Mind Medicine Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), a US-based biotech company developing psychedelic-inspired therapies, announced on Friday that it has started Phase 2a proof-of-concept (PoC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit hyperactivity disorder (ADHD).
The company has activated its first site and patient enrolment is expected to commence immediately.
The Phase 2a PoC trial will be conducted in partnership with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands, and is aimed at assessing the therapeutic utility of repeated low doses of LSD. This is a multicentre, randomised, double-blind, placebo-controlled Phase 2a trial assessing the safety and efficacy of low-dose LSD as treatment for ADHD in adults. The trial is planning to enrol a total of 52 patients that will receive 20µg of LSD (every (dose schedule) or placebo for six weeks (twice a week on a 3/4-day schedule [± 1 day]). Dr. Matthias Liechti, at University Hospital Basel, Switzerland and Dr. Kim Kuypers at Maastricht University, the Netherlands are to head the trial.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration